Ebola Vaccines Market – Rising Ebola Mortality Rates Expected To Be A Major Factor In Market Growth

The CMI published a commercial research report on “Ebola Vaccines Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2021-2027”. Ebola vaccine with over 100 market data tables, pie chat, graphs and figures spread over pages and easy to understand detailed analysis. The information is collected on the basis of modern floats and requests identified with administrations and posts.

The Ebola Vaccine market report comprises historical data, current market trends, environment, technological innovation, upcoming technologies, and technical advancements in the related industry. Ebola vaccine market offers a comprehensive and knowledgeable report providing relevant market research data for new market entrants or incumbent players. The key strategies of the companies operating in the market and their impact analysis have been included in the report.

Get your FREE copy of the 2021 Ebola Vaccines Market Report

Ebola virus disease is one of the deadliest diseases and affects both human and non-human primates. It is a fatal disease caused by direct contact with the bodily fluids of an infected person. Fever, vomiting, sore throat, headache, diarrhea and body aches are some of the most common symptoms of Ebola virus disease. There is no cure for Ebola virus disease, however, the symptom can be controlled by maintaining electrolyte balance, imagining the level of oxygen required, and treating the infection. Vaccines to prevent Ebola virus disease are under development.

Rising Ebola Disease Cases and Growing Vaccine Development Initiatives Expected to Fuel Market Growth

The increase in death rates from Ebola is the main factor fueling the growth of the market. According to the World Health Organization, in January 2018, about 50% of people infected with EVD died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal and Mali, Nigeria have been affected by EVD. In 2014-2016, an epidemic in West African countries such as Siberia, Leone and Guinea resulted in the deaths of around 11,300 people. Some cases were seen during the 2014-2016 epidemic in the United States, Spain, Italy and the United Kingdom among people who traveled to affected countries.

African countries and people who have been in contact with infected patients. In May 2017, WHO declared an EVD epidemic in the Democratic Republic of the Congo. There are still fears of a potential outbreak of VCA in vulnerable regions of West Africa that have already faced an outbreak of EVD due to gaps in public health infrastructure. Various institutes and pharmaceutical companies are focusing on the development of EVD vaccines. According to a study published in The Lancet journal in December 2016, the rVSV-ZEBOV vaccine, also known as the V920 vaccine, jointly developed by Newlink Genetics and Merck and Company, has been shown to be effective in protecting against EVD in during the phase three trial. RVSV-ZEBOV uses a strain of Ebola virus from Zaire. Merck plans to file a final marketing authorization application for its EVD vaccine with the US FDA in 2018. In addition, it has produced 3,000,000 vaccines, in the event of a new epidemic in vulnerable regions. Several key manufacturers are focusing on the production of EVD vaccines, in order to expand their presence in the market. For example, GlaxoSmithKline developed the CAd3-ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by the National Institute of Allergic and Infectious Diseases, which began its phase three trials in February 2016. Ad26-ZEBOV’s Janssen Pharmaceutical is an investigational vaccine under development and currently in phase one. In 2014, Novavax Inc. developed the Ebola vaccine using its proprietary recombinant technology.

Buy this premium report now to grow your business: https://www.coherentmarketinsights.com/insight/buy-now/1365

Reasons to buy this report

• Current and future outlook of the global Ebola vaccine market in developed and emerging markets.
• The segment which is expected to dominate the market as well as the segment which holds the highest CAGR during the forecast period.
• Regions / countries expected to experience the fastest growth rates during the forecast period
• The latest developments, market shares and strategies used by the main market players

“Limited time offer”

Access an in-depth study with over 150 pages, a list of tables and figures, profiling over 20 companies.
We also offer 15% FREE customization of reports.
Get this premium report with an instant discount of US $ 2000 @ https://www.coherentmarketinsights.com/promo/buynow/1365

Market segmentation

By viral strain, the global Ebola vaccine market is segmented into:

  • Recombinant vesicular stomatitis virus-Zaire Ebola virus
  • Chimpanzee Adeno virus type 3-Zaire Ebola virus
  • Adenovirus serotype 26- Zaire Ebola virus

In January 2018, GeoVax Labs Inc. published the results tested in non-hamate primates for its investigational vaccine, GEO-EM01 against EVD. It is based on the company’s new Vaccinia Ankara (VLP) Modified Viral-Like Particle (VLP) platform, which produces non-infectious VLPs in the bodies of vaccinated individuals.

This VLP mimics natural infection, which triggers the body to produce an immune response with both antibodies and T cells. GAVI is an international organization (Global Vaccine Alliance) paid US $ 5 million to Merck & Company in 2016 for the purchase of the vaccine (vaccine V 920). The major players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline and Novavax Inc.

Key Highlights of the Ebola Vaccines Market Report Table of Contents

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Scope of the research
1.4 Market Analysis by Regions
1.5 Global Ebola Vaccines Market Size Analysis from 2021 to 2027
11.6 COVID-19 outbreak: impact on the Ebola vaccine industry

Chapter 2 Global Ebola Vaccine Competition by Types, Applications and Major Regions and Countries
2.1 Global Ebola Vaccine (Volume & Value) by Type
2.3 Global Ebola Vaccine (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional production market analysis

Chapter 4 Global Ebola Vaccine Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Ebola Vaccines Market Analysis
Chapter 6 East Asia Ebola Vaccines Market Analysis
Chapter 7 Europe Ebola Vaccines Market Analysis
Chapter 8 South Asia Ebola Vaccines Market Analysis
Chapter 9 Southeast Asia Ebola Vaccines Market Analysis
Chapter 10 Middle East Ebola Vaccines Market Analysis
Chapter 11 Africa Ebola Vaccines Market Analysis
Chapter 12 Oceania Ebola Vaccines Market Analysis
Chapter 13 South America Ebola Vaccines Market Analysis
Chapter 14 Company Profiles and Key Figures of the Ebola Vaccine Sector
Chapter 15 Global Ebola Vaccines Market Forecast (2021-2027)
Chapter 16 Conclusions
Research methodology

Request for analysis of the impact of COVID-19 on the Ebola vaccine market – https://www.coherentmarketinsights.com/insight/request-sample/1365

The main points covered in the Ebola vaccine market study are as follows: –

• What will be the market growth rate, overview and analysis by type of Ebola Vaccine market in 2026?
• What are the key factors driving the Ebola Vaccine market?
• What is dynamics, this overview comprises scope analysis and price analysis of key manufacturer profiles of the Ebola Vaccine Market?
• Who are the opportunities, risks and driving force behind the Ebola Vaccine market? Knows the upstream raw material supply and downstream buyers
• Who are the main suppliers in the Ebola vaccine market? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Ebola Vaccine Market opportunities and threats faced by the vendors in the market?

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients of all backgrounds, from Fortune 500 companies to nonprofits and startups looking to enter the market. We excel in providing unmatched actionable market insights across various industry verticals including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, customized research solutions and advisory services.


Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837

About Clara Barnard

Check Also

Eliminate the sting of cryptocurrencies

scaliger/iStock Editorial via Getty Images Introduction Faced with structurally slower long-term economic growth cause by …